Clinical trial
A Randomized Phase 2/3 Study of Apatinib as Third Line Treatment in Patients With Metastatic Gastric Carcinoma
NCT00970138 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2/3 Study of Apatinib as Third Line Treatment in Patients With Metastatic Gastric Carcinoma
- Lead sponsor
- Fudan University
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- June 30, 2009
- Completion date
- December 31, 2010
- Enrollment
- 141 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
gastric carcinoma